HB 4423 requires the Oklahoma Health Care Authority to verify the immigration status of all Medicaid applicants using the federal SAVE system (or its successor) before approving benefits. It specifically mandates that the Authority notify U.S. Immigration and Customs Enforcement (ICE) if an applicant's status cannot be verified as lawful. This applies to all applicants, including adults applying for child-only Medicaid benefits on behalf of a child. The bill takes effect October 1, 2026, and does not change Medicaid eligibility criteria but adds a verification step for immigration status.
SB 1425 repeals three existing Oklahoma statutes related to health care workforce programs: 70 O.S. 2021 §2640 (Oklahoma Health Care Workers and Educators Assistance Program) and 74 O.S. 2021 §§3200.1-3200.2 (Health Care Workforce Resources Act). This bill eliminates the legal framework for these specific programs, which previously provided assistance to health care workers and educators. The repeal takes effect on November 1, 2026, and directly affects the administrative structure and operations of those programs. No new provisions or funding are created; the bill solely removes the existing laws.
HB 3834, the "Oklahoma Breakthrough Therapy Act," establishes a framework for ibogaine clinical trials in Oklahoma. It requires drug developers to match state funding for trials, provide detailed plans for FDA approval and post-approval patient access (including priority for state residents and low-income care), and share intellectual property proceeds with the state. These proceeds fund an "Ibogaine Intellectual Property Account" managed by the State Treasurer, which must be spent on programs for at-risk populations with conditions treatable by ibogaine (like opioid use disorder). The bill also protects Oklahoma-licensed medical professionals from adverse licensing actions for recommending ibogaine therapy.
HB 3767 adds specific synthetic drugs and substances to Oklahoma's Schedule I and IV of controlled dangerous substances under state law. It directly affects anyone possessing, distributing, or using the newly listed compounds, including various fentanyl analogs (like para-fluorofentanyl), synthetic hallucinogens (like psilocybin and salvia), and other novel psychoactive substances. The bill amends Oklahoma's Controlled Dangerous Substances Act by expanding the official lists in Schedule I (substances with no medical use and high abuse potential) and Schedule IV (substances with accepted medical use but potential for abuse). This creates new legal prohibitions for these substances without requiring additional medical or legal exceptions.
HB 2749 creates a special fund called the Intergenerational Education Revolving Fund within the Oklahoma Health Care Authority. It establishes a competitive grant program to connect nursing facilities participating in Oklahoma's Medicaid program with public school districts for collaborative intergenerational education initiatives. Grant awards, provided as rate adjustments to qualifying facilities, will fund these partnerships. The program begins July 1, 2025, with funds limited to the total amount deposited into the revolving fund.
SB 1428 creates the Office of Alzheimer’s Disease and Related Dementia Service Coordination within Oklahoma’s State Department of Health, effective November 1, 2026. The office will coordinate statewide dementia services, eliminate duplicated efforts, collect data, support staff training, and identify grant opportunities to improve care for individuals with Alzheimer’s or related dementias and their caregivers. It requires the office to maintain a full-time dementia services coordinator position to manage operations. The bill repeals two outdated sections of Oklahoma law (63 O.S. 2021, Sections 1-879.2 and 1-879.3) related to dementia services.
HB 1168 makes it a felony to knowingly deliver or possess abortion-inducing drugs (like misoprostol or methotrexate) with the intent of causing an abortion, punishable by up to $100,000 in fines or 10 years in prison. It directly affects individuals who provide such drugs for non-exceptional purposes, including off-label use for abortion. Key exceptions include pharmacists, manufacturers, and distributors acting within lawful medical practices, as well as preventive contraception used as directed by manufacturers. The law does not restrict treatment for ectopic pregnancies, miscarriages, or medical uses of drugs like chemotherapy.
SB 1255 requires Oklahoma's Department of Corrections medical director to certify qualifying medical conditions and request the Pardon and Parole Board to place eligible inmates on a special docket for compassionate parole consideration. It directly affects inmates with specific terminal or debilitating conditions like dementia, cancer, HIV/AIDS, or conditions causing near-death (six-month life expectancy), or those unable to perform basic self-care. The bill bypasses the standard two-step parole hearing process for these inmates and mandates that at least three Board members must concur to consider medical parole. The Board must document concurrence in meeting minutes, and parolees may face revocation if their medical condition poses public safety risks.
HB 3143 extends Oklahoma's moratorium on new medical marijuana business licenses (dispensaries, processors, growers) from August 1, 2026, to August 1, 2028. It requires existing license holders to get written approval from the Oklahoma Medical Marijuana Authority before transferring ownership, including submitting documentation to the Oklahoma State Bureau of Narcotics. Transfers must follow a 15-business-day timeline for license and registration changes, and applicants cannot submit transfer requests if disciplinary actions are pending. The bill also mandates that businesses provide a full inventory of all medical marijuana products during ownership changes and prohibits transfers without approval, with a 30-day window for pending applications to comply with new rules.
SB 1344 creates Oklahoma's Insulin Access and Affordability Program, administered by the State Department of Health, to increase access to affordable insulin for residents. The bill requires the Department to provide financial support to a nonprofit pharmaceutical manufacturer developing fast-acting biosimilar insulin, contingent on the manufacturer matching funds and agreeing to produce insulin at low cost without rebates (except as required by law). The agreement includes annual reporting on development progress and repayment terms if the insulin isn't produced and distributed as promised. This program directly affects Oklahoma residents needing insulin, public and private payors, and the specified nonprofit manufacturer.
